Amylyx Pharmaceuticals, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Amylyx Pharmaceuticals, Inc. (AMLX) had Lessee, Operating Lease, Liability, to be Paid, Year One of $1.85 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-03
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $1.85M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $1.59M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $2.48M.
- 2023-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $2.48M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $1.85M 10-K · filed 2026-03-03 |
| 2024-12-31 | $1.59M 10-K · filed 2025-03-04 |
| 2023-12-31 | $2.48M 10-K · filed 2024-02-22 |
| 2023-09-30 | $2.48M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.48M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.48M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.42M 10-K · filed 2023-03-13 |
| 2022-09-30 | $2.42M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.42M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.42M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |